mitomycin c
AssetAlso UGN-102, UGN-103, UGN-104, NSC-26980
Cross-links DNA, inhibiting DNA synthesis and causing cancer cell death.
- Stage
- Approved
- Modality
- Small molecule
- Target
- Apoptosis
- 10
- Indications
- 162
- Trials
- 1
- Developer
Indications
10Glaucoma Surgery
Approved, accessdata.fda.gov, Oct 17, 2026
Non-Muscle Invasive Bladder Cancer
Approved, accessdata.fda.gov, Oct 17, 2026
Urothelial cancer
Approved, accessdata.fda.gov, Oct 17, 2026
7 more
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials162
- Evidence for its targets2
- Competitors12
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.